fig1

Non-viral gene therapy for neuromuscular diseases including Duchenne muscular dystrophy using nanovesicles derived from human cells

Figure 1. Derived from human cells, nanovesicles are highly bio-friendly substance with excellent safety profiles as compared to foreign carriers. Allogeneic nanovesicles from diverse human cell sources are well-tolerated in human patients.

Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/